AbCellera Biologics Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.99B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M). The key difference: AbCellera Biologics Inc is far larger — about 195× Avalanche Treasury Corporation Class A Common Stock's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ABCL | AVAT | |
|---|---|---|
Market Cap | $2.99B | $15.33M |
Sector | Health | Financials |
52-Week High | $9.76 | $10.75 |
52-Week Low | $2.78 | $0.30 |
Enterprise Value | $2.58B | $15.33M |
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →